RECAP - Stock Plunges on Aggressive 2026 Guidance Novo Nordisk Faces a Pivotal Year: Stock Plunges on Aggressive 2026 Guidance - A Buying Opportunity or a Red Flag?
The pharmaceutical sector was jolted on Tuesday as Novo Nordisk A/S (NYSE: NVO), the Danish titan behind blockbuster GLP-1 drugs Ozempic and Wegovy, saw its share price tumble nearly 15
Novo Nordisk A/S Class B
No trades
Key facts today
Novo Nordisk's Wegovy 1.5 mg weight loss pill is now priced at $149 for a 30-day supply, down from $1,349, as part of a cost-reduction initiative.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.075 EUR
13.68 B EUR
41.29 B EUR
3.17 B
About Novo Nordisk A/S Class B
Sector
Industry
CEO
Maziar Mike Doustdar
Website
Headquarters
Bagsværd
Founded
1923
IPO date
May 17, 1974
Identifiers
2
ISIN DK0062498333
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
NVO Alert: Quick Downside Opportunity📉 NVO Weekly Trade (Speculative Bearish)
Direction: Short / Put
Instrument: NVO $62 Put
Expiry: Jan 30, 2026 (Friday)
Entry Zone: $1.65 – $1.72
🎯 Targets
Target 1: $2.06 (+25%) → scale 50%
Target 2: $2.64 (+60%+) → use trailing stop
Risk: Stop loss: $1.29
Hard exit: NVO above $64.16
Notes /
NVO Bullish reversalNVO has started its journey of bullish reversal FINALLY
2026 is the year of NVO strong come back
64 is a very strong resistance , if it closes the daily candle above 64 then we are easily looking at next stop
Enter once its confirmed daily close above 64 with stop loss 58 and ride the wave of
Novo Nordisk about to finish accumulation range?As the title says. Looks like NYSE:NVO is finishing up an relative small accumulation range. Question is whether the spring-test is done here or not. Sometimes there's a big push and retrace to create a test. Sometimes something that resembles current PA can be enough.
Let's see how it develops.
Double bottom with a potential double‑up The price dropped sharply after the company projected a revenue decline for 2026.
A perfect double bottom has formed around $43, and now it’s just waiting for a breakout above the neckline to project a target toward $81.5.
Someone more famous than me once said: “Be greedy when others are fearful,
$NVO — another upside breakout today. Still holding the full posNYSE:NVO — another upside breakout today. Still holding the full position, now with a large open profit.
The Danish primary listing of Novo Nordisk, OMXCOP:NOVO_B , is now trading in clear air. The 460 DKK area looks like the most logical swing target, which aligns slightly above my $70 zone on t
NVO BEARISH TO BULLISHNVO forming a potential reversal setup: currently showing signs of transitioning from bearish to bullish. Looking for confirmation of trend change before entering long.
the confirimation would be seeing nvo breaking the current resistence
also, sidenote, SMA 150 AND SMA 20 have crossed, thats a goo
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
XS323295972
Novo Nordisk Finance (Netherlands) BV 4.0% 20-NOV-2045Yield to maturity
4.26%
Maturity date
Nov 20, 2045
N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037Yield to maturity
3.75%
Maturity date
May 27, 2037
N
XS323295590
Novo Nordisk Finance (Netherlands) BV 3.625% 20-FEB-2038Yield to maturity
3.74%
Maturity date
Feb 20, 2038
N
XS323294453
Novo Nordisk Finance (Netherlands) BV 3.375% 20-FEB-2035Yield to maturity
3.49%
Maturity date
Feb 20, 2035
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034Yield to maturity
3.38%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033Yield to maturity
3.17%
Maturity date
May 27, 2033
N
XS323293716
Novo Nordisk Finance (Netherlands) BV 3.0% 20-FEB-2032Yield to maturity
3.09%
Maturity date
Feb 20, 2032
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031Yield to maturity
2.91%
Maturity date
Jan 21, 2031
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030Yield to maturity
2.89%
Maturity date
Aug 27, 2030
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030Yield to maturity
2.69%
Maturity date
Mar 31, 2030
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028Yield to maturity
2.62%
Maturity date
May 27, 2028
See all NOV bonds
MEUH
Amundi Core Stoxx Europe 600 -UCITS ETF HEDGED- CapitalisationWeight
1.25%
Market value
243.36 M
USD
STXH
Amundi Index Solutions SICAV - Amundi Core Stoxx Europe 600 UCITS ETF Monthly Hedged to EUR - Dist- DistributionWeight
1.25%
Market value
243.36 M
USD
Explore more ETFs
Frequently Asked Questions
The current price of NOV is 39.545 EUR — it has increased by 5.37% in the past 24 hours. Watch Novo Nordisk A/S Class B stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange Novo Nordisk A/S Class B stocks are traded under the ticker NOV.
NOV stock has fallen by −20.64% compared to the previous week, the month change is a −18.12% fall, over the last year Novo Nordisk A/S Class B has showed a −52.71% decrease.
We've gathered analysts' opinions on Novo Nordisk A/S Class B future price: according to them, NOV price has a max estimate of 72.12 EUR and a min estimate of 30.72 EUR. Watch NOV chart and read a more detailed Novo Nordisk A/S Class B stock forecast: see what analysts think of Novo Nordisk A/S Class B and suggest that you do with its stocks.
NOV stock is 5.80% volatile and has beta coefficient of 1.64. Track Novo Nordisk A/S Class B stock price on the chart and check out the list of the most volatile stocks — is Novo Nordisk A/S Class B there?
Today Novo Nordisk A/S Class B has the market capitalization of 166.57 B, it has decreased by −7.71% over the last week.
Yes, you can track Novo Nordisk A/S Class B financials in yearly and quarterly reports right on TradingView.
Novo Nordisk A/S Class B is going to release the next earnings report on May 6, 2026. Keep track of upcoming events with our Earnings Calendar.
NOV earnings for the last quarter are 0.81 EUR per share, whereas the estimation was 0.78 EUR resulting in a 2.81% surprise. The estimated earnings for the next quarter are 0.69 EUR per share. See more details about Novo Nordisk A/S Class B earnings.
Novo Nordisk A/S Class B revenue for the last quarter amounts to 10.57 B EUR, despite the estimated figure of 10.27 B EUR. In the next quarter, revenue is expected to reach 9.81 B EUR.
NOV net income for the last quarter is 3.59 B EUR, while the quarter before that showed 2.67 B EUR of net income which accounts for 34.38% change. Track more Novo Nordisk A/S Class B financial stats to get the full picture.
Novo Nordisk A/S Class B dividend yield was 3.60% in 2025, and payout ratio reached 50.75%. The year before the numbers were 1.83% and 50.28% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Feb 7, 2026, the company has 68.79 K employees. See our rating of the largest employees — is Novo Nordisk A/S Class B on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novo Nordisk A/S Class B EBITDA is 20.03 B EUR, and current EBITDA margin is 48.43%. See more stats in Novo Nordisk A/S Class B financial statements.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novo Nordisk A/S Class B stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novo Nordisk A/S Class B technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novo Nordisk A/S Class B stock shows the strong sell signal. See more of Novo Nordisk A/S Class B technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.









